ReviewFrontiers in oncology2026
A narrative review of new strategies for immunotherapy combination treatment in platinum-resistant ovarian cancer: mechanisms, clinical evidence, and future directions.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platinum-resistant ovarian cancer (PROC) is a major challenge in gynecological tumor treatment, with poor prognosis and limited chemotherapy efficacy. Immune checkpoint inhibitors as monotherapy demonstrate low response rates, underscoring the need for effective combination therapies. This review aims to describe recent advances in immune combination therapy for PROC, explain synergistic mechanisms, summarize key clinical evidence, and discuss challenges and future directions. The search of PubMed and Web of Science (January 2018-January 2026) following PRISMA guidelines identified phase II/III trials, prospective cohorts, and preclinical studies. The narrative review found that combination strategies with anti-angiogenic agents achieved objective response rates (ORR) of 24-27% and median progression-free survival (PFS) of 4-5 months. Adding PARP inhibitors yielded an ORR of 18-31% with disease control rates of 65-81%. Furthermore, the antibody-drug conjugate (ADC) mirvetuximab soravtansine as monotherapy achieved an ORR of 42.3% in folate receptor alpha (FRα)-high PROC. Finally, the phase III KEYNOTE B96 trial reported a 4.2-month overall survival benefit with pembrolizumab plus chemotherapy in the PD-L1-positive population. These regimens substantially improve efficacy compared with historical single-agent chemotherapy (ORR 10-20%, PFS 3-4 months). In conclusion, immune combination therapy offers a novel therapeutic strategy for PROC. Future efforts should explore biomarkers, optimize regimens, overcome resistance, and validate efficacy through innovative trials to achieve personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.